Genmab A/S (GMAB)
| Market Cap | 12.46B |
| Revenue (ttm) | 2.99B |
| Net Income (ttm) | 1.09B |
| Shares Out | 63.54M |
| EPS (ttm) | 16.85 |
| PE Ratio | 11.44 |
| Forward PE | 12.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,135,318 |
| Open | 19.43 |
| Previous Close | 19.55 |
| Day's Range | 19.43 - 20.16 |
| 52-Week Range | 17.24 - 30.41 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | 39.17 (+100.36%) |
| Earnings Date | May 8, 2025 |
About GMAB
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was 21.53 billion, an increase of 30.67% compared to the previous year's 16.47 billion. Earnings were 7.84 billion, an increase of 80.24%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $39.17, which is an increase of 100.36% from the latest price.
News
Genmab's Outlook Beyond Darzalex's Patent Cliff
Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company's robust late-stage pipeline could offset DAR...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
Company Announcement Net sales of DARZALEX ® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen B...
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; April 14, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million sha...
Genmab A/S Share Capital Reduction
Company Announcement COPENHAGEN, Denmark; April 10, 2025 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 12, 2025, it was decided to reduce the Company's share capital with ...
Transactions In Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shar...
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; April 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, thi...
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK ® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or ...
Transactions in connection with share buy-back program
Company Announcement COPENHAGEN, Denmark; March 31, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million sha...
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S' GMAB Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after cancer c...
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
Media Release COPENHAGEN, Denmark; March 27, 2025 TIVDAK ® is the first and only antibody-drug conjugate (ADC) approved for patients with advanced or recurrent cervical cancer in Japan Approval is bas...
Genmab Announces Initiation of Share Buy-Back Program
Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billion Reduce the capital of Genmab and honor our commitments under the Restricted Stock Un...
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle) Genmab categorically refutes allegations and will vigorously...
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational fola...
Genmab: GEN3014's Demise And Implications For The HexaBody Platform
Genmab's stock fell after J&J opted out of developing GEN3014 due to its undifferentiated efficacy and worse safety and tolerability compared to Darzalex. Genmab wisely chose not to pursue GEN3014 fur...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, th...
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 12, 2025, the Company's Board of Directors met to consti...
Passing of Genmab A/S' Annual General Meeting
Company Announcement At Genmab A/S' Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approved Discharge was given to the Board of Directors and the Executive Management...
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop,...
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and empl...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The incr...
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
Media Release COPENHAGEN, Denmark; February 20, 2025 Approval based on results from two Phase 1/2 EPCORE ® clinical trials, which demonstrated strong and durable efficacy in patients with relapsed or ...
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
Media Release COPENHAGEN, Denmark; February 19, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its C hief F inancial O fficer Anthony Pagano and C hief D evelopment O fficer Judith Klimovsky wil...
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of conse...
Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript
Genmab A/S (GMAB) Q4 2024 Earnings Conference Call February 12, 2025 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Tahamt...
Notice to Convene the Annual General Meeting of Genmab A/S
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wedn...